Tag: Neovasc

German NUB Status 1 designation for Neovasc Reducer renewed

Neovasc has announced that the Institut für das Entgeltsystem im Krankenhaus (InEk)— the German Inst...

TMVI with Tiara valve may be safe and feasible for patients with prior aortic valve replacement

A new study indicates that transcatheter mitral valve implantation (TMVI) with the Tiara valve (...

Safety and efficacy results of REDUCE study published in International Journal of Cardiology

The manuscript “Safety and efficacy of the Reducer: A multicentre clinical registry—REDUCE study...

TVT 2018: Tiara TMVI device featured in live case

Neovasc announced that its Tiara transcatheter mitral valve implantation (TMVI) device was featu...

Neovasc receive approval to initiate COSIRA-II IDE clinical trial

Neovasc has received approval of the US FDA to initiate the COSIRA-II IDE clinical trial.  The trial...

Neovasc provides Tiara clinical update

Neovasc has provided an update on the study progress and clinical performance of the Tiara valve...

German court awards Edwards Lifesciences co-entitlement of Neovasc’s Tiara patent application

The District Court in Munich, Germany has partially found in favour of Edwards Lifesciences Corp...

Boston Scientific closes acquisition of certain Neovasc assets

Boston Scientific Corporation has closed its acquisition of certain manufacturing assets and cap...

Boston Scientific to acquire Neovasc biological tissue capabilities

Boston Scientific has agreed to acquire certain manufacturing assets and capabilities of the Neo...

Neovasc receives approval to launch European study of Tiara transcatheter mitral valve

Neovasc has received both regulatory and ethics committee approval to initiate the Tiara transca...